average weight loss with glp-1 agonists Rx Trends: Real-World Data on GLP-1s for What You Need to Know

The emerging evidence of the Parkinson pandemic

Compared to GLP-1 RAs, SGLT2is (WMD: 0.43

DPP-4 inhibitors did not lower the risk of any cardiorenal outcome when compared with placebo and were associated with higher risks of MACE, HHF, and renal outcome when compared with the other two drug classes

GLP-1 drugs can help lower the amount of insulin a person requires to control their blood sugar and may help people who have type 1 and obesity to lose weight

Recent research has indicated that using DPP4is together with angiotensinconverting enzyme (ACE) inhibitors for an extended period might have a synergistic effect, potentially increasing the risk of lung cancer [173]